Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
In the Interim...
Berry
The AFTA Podcast
AFTA
UFO to UAP Podcast
Matt Tones
Situs Inversus – Der Vorklinik-Podcast
Team Situs Inversus
Bright Side
TheSoul Publishing
Τα podcasts του Newshub.gr
newshub.gr
Galactic Horrors
Galactic Horrors
Dark Mysteries — Unsolved Mysteries. Forgotten Secrets. Unanswered Questions.
Darkest Mysteries Online
Unleashing Intuition Secrets
Michael Jaco
Intelligent Design the Future
Discovery Institute
Fish of the Week!
U.S. Fish and Wildlife Service
The Astrocast
Christopher Page
GL DEEP DIVES
Gorgorod
Horticulture Innovators
Texas A&M Horticultural Sciences Department
Thrilling Threads - Conspiracy Theories, Strange Phenomena, True Crime, Unsolved Mysteries, etc!
Byte & Pieces
The Hanania Show
Richard Hanania
R2Kast - People in Food and Farming/All In
Wallace Currie
Scientific Health: Education and Human Performance
Scientific Health: Education and Human Performance
Gordon's Lebanon Weather Forecast
Gordon's Lebanon Forecast 121523
TED-Ed
TED-Ed
Almond Journey
Almond Journey
Betreutes Fühlen
Atze Schröder & Leon Windscheid
My Weird Prompts
Daniel Rosehill
The Charlie & Duke Show
Eat Sleep Elite
Cose Molto Umane di Gianpiero Kesten
Gianpiero Kesten - Vois
Medical News Podcast
PeerDirect
Real Ghost Stories Online
Real Ghost Stories Online | Paranormal, Supernatural & Horror Radio
What is The Future for Cities?
Fanni Melles
The 40k Lorecast
Warhammmer 40k
Permaculture P.I.M.P.cast
Permaculture P.I.M.P.cast
PBS Space Time
PBS
Arquicast
Arquicast
STAT Stitch Deep Dive Podcast Beyond The Bedside
Regular Guy
BioCentury This Week
BioCentury
Aha! Zehn Minuten Alltags-Wissen
WELT
Logically Answered
Logically Answered
Ur ❤️ Speaks
Kato Caleb
Ciencia
Berry
On the latest episode of "In the Interim...", Dr. Scott Berry and Dr. Kert Viele deliver a focused, technical analysis of statistical bias when stopping trials early. This episode clarifies the definition of bias, detail...
On the latest episode of "In the Interim…", Dr. Scott Berry provides an empirical examination of two recent JAMA trials: TRACK (low-dose rivaroxaban in advanced kidney disease) and VICTORY (IV vitamin C in severe burn in...
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele examine response-adaptive randomization (RAR) in clinical trials, dissecting its statistical rationale, common criticisms, and implementation chall...
In this episode of "In the Interim…", Dr. Scott Berry explores the origins of REMAP-CAP with Prof. Steve Webb, former chair of the REMAP-CAP International Trial Steering Committee. This episode examines how pandemic prep...
In this episode of "In the Interim…", Dr. Scott Berry explores the challenge of protracted endpoint timelines in adaptive clinical trials and the statistical strategies used to increase the rate of actionable information...
In this episode of "In the Interim…", Dr. Scott Berry is joined by Dr. Will Meurer, professor of Emergency Medicine and Neurology at the University of Michigan, for an in-depth discussion of the ICECAP trial’s adaptive B...
In this episode of "In the Interim…", Dr. Scott Berry details the design, execution, and results of the multi-platform randomized clinical trial (mpRCT) pioneered during the COVID-19 pandemic. He describes how REMAP-CAP,...
In this episode of "In the Interim…", Dr. Scott Berry examines the analytical challenges of comparing performance across eras in both sports and clinical research. Drawing from statistically robust family debates and pub...
In the 60th episode of “In the Interim…”, Dr. Scott Berry, Dr. Nick Berry, and Dr. Joe Marion discuss how Berry Consultants uses AI in clinical trial design and software development. The conversation addresses current ap...
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Nick Berry investigate how futility in clinical trials and stopping rules in sports illuminate very similar decision problems, albeit with very different cons...
In this episode of "In the Interim…", host Dr. Scott Berry undertakes a detailed, methodical critique of ICH-E20 draft guidance language as applied to adaptive clinical trial design. Focusing on an innocuous but corrupti...
In this episode of "In the Interim…" Dr. Scott Berry is joined by Professors Victoria Cornelius, Danny McAuley, and Anthony Gordon, for a technical review of the PANTHER trial—an international, Phase 2 adaptive platform ...
In this episode of "In the Interim…", Dr. Scott Berry connects with Dr. Byron Gajewski, professor of biostatistics and data science at the University of Kansas Medical Center (KUMC), for a detailed discussion on the desi...
In this episode of "In the Interim...", Dr. Scott Berry hosts Dr. Stephen Senn, award-winning statistician and author, for a discussion on advanced challenges in adaptive and platform trial methodology. Senn draws on exp...
In this episode of "In the Interim…", Dr. Scott Berry is joined by statisticians Dr. Amy Crawford, Dr. Cora Allen-Savietta, and Dr. Jessica Overbey for a technical deep dive into hierarchical composite endpoints and the ...
In this episode of "In the Interim…", Dr. Scott Berry interviews Professors Steven Tong and Josh Davis about the SNAP platform trial for Staphylococcus aureus bacteremia. The discussion covers SNAP’s rationale, large-sca...
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele examine Bayesian borrowing in Phase 3 clinical trials, focusing on statistical handling of prior information and real-world FDA interactions. The e...
In Episode 51 of "In the Interim…", Dr. Scott Berry interviews writer, producer, and performer Shaun Cassidy to examine the practical elements of storytelling that matter in scientific and statistical communication. Cass...
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Lindsay Berry investigate the statistical foundations and clinical implications of analyzing ordinal endpoints, drawing on experience from major stroke and CO...
In this episode of "In the Interim…", Dr. Scott Berry marks the podcast’s one-year anniversary, sharing listener metrics, watch data, and regional engagement. He then delivers a step-by-step analysis of the FDA meeting p...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.